The company’s clinical pipeline also includes ADX-2191, a dihydrofolate reductase inhibitor in Phase 3 testing for proliferative vitreoretinopathy, and ADX-1612, a chaperome inhibitor in Phase 2 ...

Methotrexate sodium tablets are a dihydrofolate reductase inhibitor indicated for the: Treatment of adults with acute lymphoblastic leukemia (ALL) as part of a combination chemotherapy maintenance ...

Its lead product candidate is reproxalap, a reactive aldehyde species (RASP) modulator, which is in Phase III clinical trial for the treatment of dry eye disease and allergic conjunctivitis; and ...

Methotrexate sodium tablets are a dihydrofolate reductase inhibitor indicated for the: Treatment of adults with acute lymphoblastic leukemia (ALL) as part of a combination chemotherapy maintenance ...

Summary and Introduction Clinical Application—Disease Entities Theoretical Framework for Therapy−The 'Steel Paradigm' Conclusion References Theoretical Framework for Therapy−The 'Steel ...

This study presents an important finding on the molecular mechanism for transduction of environmentally induced polyphenism. The evidence supporting the claims of the author is solid. This paper would ...

College of Biotechnology and Bioengineering, Zhejiang University of Technology, Hangzhou, Zhejiang 310032, China Zhejiang Key Laboratory of Green Manufacturing Technology for Chemical Drugs, Deqing, ...